Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Breast Cancer. 2014 Apr;14(2):132-40. doi: 10.1016/j.clbc.2013.10.010. Epub 2013 Oct 25.

The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.

Author information

1
City of Hope National Medical Center, Duarte, CA. Electronic address: ahurria@coh.org.
2
City of Hope National Medical Center, Duarte, CA.
3
University of California, Los Angeles, CA.

Abstract

INTRODUCTION:

This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission tomography (PET) scans of the brain done in a subset of the patient cohort.

PATIENTS AND METHODS:

Thirty-five patients (32 evaluable) and 35 healthy controls were recruited to this study. Patients with breast cancer completed a neuropsychological battery, self-reported memory questionnaire, and geriatric assessment before initiation of AI therapy and again 6 months later. Age-matched healthy control participants completed the same assessments at the same time points as the patient group.

RESULTS:

No significant decline in cognitive function was seen among individuals receiving an AI from pretreatment to 6 months later compared with healthy controls. In the PET cohort over the same period, both standardized volume of interest and statistical parametric mapping analyses detected specific changes in metabolic activity between baseline and follow-up uniquely in the AI patients, most significantly in the medial temporal lobes.

CONCLUSION:

Although patients undergoing AI treatment had few changes in neuropsychological performance compared with healthy controls over a 6-month period, regionally specific changes in cerebral metabolic activity were identified during this interval in the patient group. Additional longitudinal follow-up is needed to understand the potential clinical implications of these findings.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00681928.

KEYWORDS:

Cognition; Elderly; Endocrine therapy; Geriatric oncology; PET scan

PMID:
24291380
PMCID:
PMC4103787
DOI:
10.1016/j.clbc.2013.10.010
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center